Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Understanding EGFR Signaling Networks May Lead to New Cancer Treatments

By LabMedica International staff writers
Posted on 20 Jun 2012
Cancer researchers have shown that a combination of drugs already approved by the [US] Food and Drug Administration (FDA) could block the oncogenic activity of EGFR (epidermal growth factor receptor) and restore drug sensitivity in advanced cases of metastatic lung adenocarcinoma.

EGFR activation is both a key molecular driver of cancer progression and the target of a broad class of molecular agents designed to treat advanced forms of the disease. More...
Nevertheless, drug resistance develops through several mechanisms, including activation of AKT signaling. AKT, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration.

Investigators at Case Western Reserve University (Cleveland, OH, USA) and colleagues at Mount Sinai School of Medicine (New York, NY, USA) characterized the downstream mediators of EGFR signaling in order to develop new classes of targeted molecular therapies to treat resistant forms of cancer.

They reported in the June 1, 2012, online edition of the Journal of Clinical Investigation that they had identified a transcriptional network involving the tumor suppressor proteins Krüppel-like factor 6 (KLF6) and forkhead box O1 (FOXO1). KLF6 and FOXO1 are tumor suppressor genes that are turned off in actively growing cancer cells.

Working with both cell culture and xenograft models of lung adenocarcinoma, the investigators showed that the use of the FDA-approved drug trifluoperazine hydrochloride (a medication used to treat schizophrenia), which had been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib (a targeted cancer drug) resistance through modulation of the KLF6/FOXO1 signaling cascade.

“Because of the financial constraints and length of time it takes to bring new drugs through clinical trials, scientists are moving toward using existing drugs in new ways so that the process of translating the discoveries of today into the treatments of tomorrow can be accelerated,” said senior author Dr. Goutham Narla, assistant professor of medicine at Case Western Reserve University.

Results of this study highlight the central importance of defining key signaling networks in cancer and the potential use of this information to identify clinically relevant modulators of treatment response.

Related Links:

Case Western Reserve University
Mount Sinai School of Medicine



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.